Wellness Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi’s SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High Risk, Molecularly Low Risk Stage 2/3 Breast Cancer Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an evaluation of SAR439859, an oral estrogen By Coast To Coast TV / June 8, 2020